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Abstract
Introduction: The growing number of renal transplant recipients in a sustained immunosuppressive state is a factor that can
contribute to increased incidence of sepsis. However, relatively little is known about sepsis in this population. The aim of
this single-center study was to evaluate the factors associated with hospital mortality in renal transplant patients admitted
to the intensive care unit (ICU) with severe sepsis and septic shock.
Methods: Patient demographics and transplant-related and ICU stay data were retrospectively collected. Multiple logistic
regression was conducted to identify the independent risk factors associated with hospital mortality.
Results: A total of 190 patients were enrolled, 64.2% of whom received kidneys from deceased donors. The mean patient
age was 51613 years (males, 115 [60.5%]), and the median APACHE II was 20 (16–23). The majority of patients developed
sepsis late after the renal transplantation (2.1 [0.6–2.3] years). The lung was the most common infection site (59.5%). Upon
ICU admission, 16.4% of the patients had#1 systemic inflammatory response syndrome criteria. Among the patients, 61.5%
presented with $2 organ failures at admission, and 27.9% experienced septic shock within the first 24 hours of ICU
admission. The overall hospital mortality rate was 38.4%. In the multivariate analysis, the independent determinants of
hospital mortality were male gender (OR = 5.9; 95% CI, 1.7–19.6; p = 0.004), delta SOFA 24 h (OR = 1.7; 95% CI, 1.2–2.3;
p = 0.001), mechanical ventilation (OR = 30; 95% CI, 8.8–102.2; p,0.0001), hematologic dysfunction (OR = 6.8; 95% CI, 2.0–
22.6; p = 0.002), admission from the ward (OR = 3.4; 95% CI, 1.2–9.7; p = 0.02) and acute kidney injury stage 3 (OR = 5.7; 95%
CI,1.9–16.6; p = 0.002).
Conclusions: Hospital mortality in renal transplant patients with severe sepsis and septic shock was associated with male
gender, admission from the wards, worse SOFA scores on the first day and the presence of hematologic dysfunction,
mechanical ventilation or advanced graft dysfunction.
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Introduction
Sepsis is the leading cause of death in non-cardiac intensive care
units, although there is some evidence of a decline in mortality
rates, at least in developed countries [1–4]. The scenario in
emerging and limited-resources countries seems to be different
with higher reported rates [5,6], although low mortality rates has
also been reported [7]. The incidence of sepsis is increasing over
the past years and the growing number of patients living with solid
organ transplants is a factor that contributes to this finding [2–
4,8].
The most common solid organ transplant procedure worldwide
is the renal transplantation. It is the treatment of choice for end-
stage renal disease. Compared with chronic dialysis, renal
transplantation is cost-effective, offers improved quality of life
and confers a progressive survival benefit [9,10]. The overall
survival rate of kidney grafts has improved consistently during the
past decades [11]. Moreover, the number of adult candidates on
the waiting lists with kidney failure continues to increase [12].
Therefore, more renal transplant recipients with functioning grafts
will be exposed to pathogens while in a sustained immunosup-
pressive state.
Because of immunosuppression, infection frequently occurs
after kidney transplantation and greatly impacts patient morbidity
and mortality. This explains why infection is the second leading
cause of death in renal transplant recipients, following cardiovas-
cular diseases [13]. The importance of infection as cause of death
is higher in underdeveloped countries [14,15]. Surprisingly,
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relatively little is known about severe sepsis in this growing
population. The aim of this study was to describe the character-
istics of severe sepsis and septic shock in renal transplant patients
who are admitted to the intensive care unit (ICU) and to evaluate
the factors associated with hospital mortality.
Materials and Methods
This single center, retrospective, observational study was
performed at a kidney transplant center in Brazil [16]. The
institutional ethics committee approved the study and waived the
informed consent requirement (Comiteˆ de E´tica em Pesquisa –
Universidade Federal de Sa˜o Paulo, reference number: 1736–10).
All consecutive adult renal transplant recipients (older than 18
years) diagnosed with severe sepsis or septic shock who were
admitted to our 12-bed ICU from June 1, 2010 to December 31,
2011 were included. We excluded pregnant patients, patients who
underwent kidney-pancreas transplantation, and patients with ‘‘do
not resuscitate’’ orders. All patients were included only in their first
episode of sepsis.
Data were retrospectively collected through medical records by
a single author (MAC). We recorded the following data: patient
demographics, comorbid chronic illnesses, severe sepsis charac-
teristics and the severity scores Sequential Organ Failure
Assessment (SOFA) and Acute Physiology and Chronic Health
Evaluation II (APACHE II). We also collected data on the initial
treatment, life support and fluid balance as well as pre-transplant,
peritransplant and post-transplant variables. We assessed adequa-
cy of treatment according to the compliance to the 6-hours
Surviving Sepsis Campaign bundle available during the study
period [17], which are similar to the recent published 3-hour and
6-hour bundles of the 2012 revised guidelines [18]. All transplant
patients in our hospital are under continuous surveillance. Thus,
the hospital database has all information about outpatient’s visits,
hospital readmissions or death in other institutions. Thus, we
collected not only the hospital mortality during the septic episode
but also the one-year survival. The database was reviewed by two
authors (FGRF and FRM). In cases of inconsistency, the sources
documents were verified, and the data were corrected. Data were
anonymized and de-identified prior to data analysis.
Severe sepsis was defined as a documented or presumed
infection plus at least one organ failure secondary to infection. We
did not use the systemic inflammatory response syndrome (SIRS)
criteria, as depressed febrile response and diminished leukocytosis
are frequently seen in solid-organ recipients [19]. Septic shock was
defined as volume-refractory hypotension with the need for
vasopressor. Organ dysfunction was diagnosed when one of the
following factors was present: hypotension with systolic blood
pressure,90 mmHg or mean arterial blood pressure,65 mmHg
(cardiovascular); arterial oxygen partial pressure/oxygen inspira-
tory fraction (PaO2/FiO2) ratio #300 (respiratory); a bilirubin
level . twice the reference value (hepatic); a lactate level $1.5
times the reference value and a base deficit .5 (metabolic); an
international normalized ratio (INR) .1.5 or a platelet count ,
100,000/mL (hematologic) and altered level of consciousness
(neurologic). To define renal dysfunction, we used increased serum
creatinine . twice the baseline value. This cutoff was arbitrary
chosen because of the lack of agreement on the definition of acute
kidney injury (AKI) in this population. In parallel, we also used the
definition recommended by Kidney Disease: Improving Global
Outcomes (KDIGO) [20] to stage AKI during the ICU stay,
without considering urine output.
The time to the sepsis diagnosis was defined as the number of
hours elapsed between the onset of the first organ dysfunction and
the recognition and management of sepsis by the healthcare
provider, as described elsewhere [21]. The severe sepsis and septic
shock treatment was analyzed based on compliance with the initial
care bundle (within the first 6 hrs of presentation) [22].
Figure 1. Study flowchart. ICU: intensive care unit.
doi:10.1371/journal.pone.0111610.g001
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Table 1. Patient characteristics and transplant variables.
All Patients (n =190) Survivors (n =117) Non survivors (n =73) p value
Age (years) 51613 50613 52613 0.300
Male gender 115 (60.5) 61 (52.1) 54 (73.9) 0.002
Body mass index (kg/m2) 2465 2565 2364 0.003
Comorbidities
Hypertension 152 (80.0) 99 (84.6) 53 (72.6) 0.040
Diabetes mellitus 61 (32.1) 39 (33.3) 22 (30.1) 0.600
CAD 35 (18.4) 24 (20.5) 11 (15.0) 0.300
Stroke 8 (4.2) 6 (5.1) 2 (2.7) 0.700
CHF 5 (2.6) 3 (2.5) 2 (2.7) 1.000
Hepatitis C 13 (6.8) 7 (5.9) 6 (8.2) 0.500
Hepatitis B 6 (3.1) 3 (2.5) 3 (4.1) 0.600
COPD 6 (3.1) 1 (0.8) 5 (6.8) 0.030
ESRD etiology 0.220
Undetermined 67 (35.2) 41 (35.0) 26 (35.6)
Glomerulonephritis 50 (26.3) 33 (28.2) 17 (23.2)
Diabetes mellitus 36 (18.9) 18 (15.3) 18 (24.6)
Hypertension 28 (14.7) 21 (17.9) 7 (9.5)
Urologic disease 9 (4.7) 4 (3.4) 5 (6.8)
Dialysis modality before transplant 0.480
Preemptive 8 (4.2) 7 (5.9) 1 (1.3)
Hemodialysis 153 (80.5) 91 (77.7) 62 (84.9)
Peritoneal 21 (11.0) 14 (11.9) 7 (9.5)
Hemodialysis/peritoneal 8 (4.2) 5 (4.2) 3 (4.1)
Time of dialysis (months) 34 (18–60) 32 (18–60) 36 (24–68) 0.170
Donor type 0.190
Deceased 122 (64.2) 71 (60.6) 51 (69.8)
Living 68 (35.8) 46 (39.4) 22 (30.2)
Donor gender a 0.330
Female 71 (42.0) 43 (40.6) 28 (44.5)
Male 98 (58.0) 63 (59.4) 35 (55.5)
Deceased donor b
Cause of death c 0.930
Traumatic brain injury 33 (28.0) 21 (30.0) 12 (25.0)
Subarachnoid hemorrhage 20 (16.9) 12 (17.1) 8 (16.6)
Stroke 56 (47.5) 32 (45.7) 24 (50.0)
Others 9 (7.6) 5 (7.2) 4 (8.4)
Panel reactive antibodies d 0.660
0–50% 93 (84.5) 55 (83.3) 38 (86.3)
.51% 17 (15.5) 11 (16.7) 6 (13.6)
Final creatinine e 0.210
,1.5 mg/dL 31 (32.6) 21 (35.5) 10 (27.7)
$1.5 mg/dL 64 (67.4) 38 (64.5) 26 (72.3)
Cold ischemia time (hours) f 23 (20–27) 23 (20–28) 22 (20–27) 0.630
Expanded criteria donor 31 (26.3) 13 (18.6) 18 (37.5) 0.020
Delayed graft function 82 (43.3) 44 (37.6) 38 (52.7) 0.040
Thymoglobulin use g 54 (28.5) 34 (29.0) 20 (27.7) 0.870
CMV disease treated 68 (35.9) 41 (35.0) 27 (37.5) 0.750
Current immunosuppression h 0.460
TAC+PRED+AZA 31 (16.3) 16 (13.6) 15 (20.5)
TAC+PRED+MF 70 (36.8) 48 (41.0) 22 (30.1)
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Statistical methods
The categorical variables are described as percentages, and the
continuous variables are described as measures of central tendency
and dispersion, according to distribution, as assessed by the
Kolmogorov-Smirnov test. We compare hospital survivors and
non-survivor using the two-tailed t-test, Mann-Whitney U-test,
chi-squared test, and Fisher’s exact test, as appropriate. Multiple
logistic regression was conducted to identify the independent risk
factors associated with hospital mortality, including all variables
with a p value ,0.10 in the univariate analysis (using a stepwise
forward regression model). The time until the sepsis diagnosis was
categorized using the best cutoff value in the receiver operating
characteristic (ROC) curve for mortality ($170 vs. ,170 min).
The number of organ dysfunctions ($2 vs. ,2) and the KDIGO
classification (stage 3 vs. stage ,3) of acute kidney injury during
ICU stay were also categorized. All variables were checked for
confounding and collinearity. The model calibration was assessed
using the Hosmer-Lemeshow test, which was considered to be
appropriate if p.0.10. We did not include the variables with
missing data .10%, as the lack of data would result in serious
inconsistencies. The patients were followed for one year, and a
mortality curve was generated using the Kaplan-Meier method-
ology. A p value,0.05 was considered to be significant. Data were
analyzed using SPSS 19.0 for Windows (SPSS, Chicago, IL, USA).
Results
During the study period, 1107 patients were admitted to the
ICU, 242 (21.9%) of whom were renal transplant patients who
were admitted for severe sepsis. Of these patients, 190 were
enrolled, as shown in Figure 1.
The patients’ characteristics and transplant variables are
summarized in Table 1. The leading causes of end-stage renal
disease were glomerulonephritis (26.3%), diabetes mellitus (18.9%)
and hypertension (14.7%), although most patients (35.2%) did not
have an identifiable cause. The majority of kidneys transplanted
were from deceased donors (64.2%). All patients had immuno-
suppression suspended at ICU admission and used hydrocortisone
(50 mg every six hours). The majority of the patients developed
sepsis late after the renal transplantation (2.1 years; range, 0.6–2.3
years). Fifty-five patients (28.9%) had histories of acute rejection
that occurred at a median of 312 days (range, 130–776 days)
before the ICU admission. The univariate analysis showed delayed
graft function, and expanded criteria donor kidneys were
associated with hospital mortality. No other clinical characteristic
related to the transplant was significantly different between the
survivors and non-survivors.
The lung was the most common site of infection (59.5%),
followed by the urinary tract (16.8%) and abdomen (9.5%)
(Table 2). We isolated the etiologic agents in the majority of the
patients (57%). Most of these agents were bacteria (Gram-
negative, 45.4%; Gram-positive: 20.4%). The other relevant
agents were Mycobacterium tuberculosis (3.7%), Cytomegalovirus
(3.7%) and fungi (24%), including Pneumocystis jirovecii (8.3%)
(Table 3).
Upon ICU admission, 16.4% of the patients had #1 SIRS
criterion (Figure 2). The most common SIRS criteria were
tachypnea (74.7%) and tachycardia (67.9%). Two or more organ
failures were present at admission in 61.5% of patients.
Respiratory and hematological dysfunctions occurred more
frequently in the non-survivors. Fifty-three patients (27.9%)
experienced septic shock within the first 24 hours of ICU
admission; however, 96 (50.5%) patients experienced septic shock
during their ICU stays. The time for severe sepsis diagnosis was
longer in the non-survivors. The patients who developed sepsis in
the ward had worse outcomes than those patients in the
emergency room (Table 2). The compliance rate with each
component of the 6-hour bundle is shown in Table 2. The
compliance rate for fluid administration (20 ml/kg crystalloid for
hypotension or lactate $36 mg/dl) was higher among the
survivors.
The clinical and biological variables at the ICU admission and
during the ICU stay are shown in Table 3. In the univariate
analysis, most of the variables were significantly different between
the survivors and non-survivors. Note that more positive fluid
Table 1. Cont.
All Patients (n =190) Survivors (n =117) Non survivors (n =73) p value
CSA+PRED+AZA 17 (8.9) 12 (10.2) 5 (6.8)
CSA+PRED+MF 7 (3.6) 4 (3.4) 3 (4.1)
TAC/CSA+PRED+EVR/SRL 4 (2.1) 3 (2.5) 1 (1.7)
SRL/EVR+PRED+MF 9 (4.7) 4 (3.4) 5 (6.8)
Others 51 (26.8) 30 (25.6) 21 (28.7)
Time between transplant and sepsis (years) 2.1 (0.6–7.2) 2.3 (0.6–7.8) 1.6 (0.6–7.0) 0.600
Acute rejection 55 (28.9) 34 (29.0) 21 (28.7) 0.960
Time rejection-sepsis (days) i 312 (130–776) 331(115–817) 282 (152–849) 0.900
CAD coronary artery disease, CHF: congestive heart failure, COPD: chronic obstructive pulmonary disease, ESRD: end-stage renal disease, CMV: cytomegalovirus, TAC:
tacrolimus, PRED: prednisone, AZA: azathioprine, MF: mycophenolate, CSA: cyclosporine, EVR: everolimus, SRL sirolimus.
a) 21 missing data,
b) 122 deceased donors,
c) 4 missing data,
d) 12 missing data,
e) final creatinine refers to the donors’ last serum creatinine level, 27 missing data,
f) 3 missing data,
g) patients who used thymoglobulin for treating rejection and/or induction in transplantation,
h) 1 missing data and i) time between the occurrence of rejection and sepsis (total of patients with rejection, 55 patients, 3 patients among the survivors and 6 among
the non-survivors were excluded for missing data). The results are expressed as number (%) or median (IQR, 25%–75%) or mean 6 standard deviation. Chi-squared test,
Mann-Whitney U-test, and Student’s t-test (univariate analysis).
doi:10.1371/journal.pone.0111610.t001
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balance at 72 hours was also associated with hospital mortality;
however this variable was not included in multiple logistic
regression due to missing data.
The basal creatinine values (before severe sepsis) were
1.9361.44 mg/dL. Four patients were under dialysis before
ICU admission because of acute Kidney dysfunction. Seventy
seven (40.5%) had renal dysfunction (increased serum creatinine.
twice the baseline value). Staging AKI according KDIGO, 48
(25.3%) patients reaching Stage 1, 27 (14.2%) a Stage 2, and 94
(49.5%) a Stage 3. There was a strong association between acute
kidney injury stage 3 and hospital mortality (Table 4). During ICU
stay, 77 (40.5%) patients underwent dialysis (conventional
hemodialysis or sustained low-efficiency dialysis). The need for
dialysis was higher among non-survivors (75.3% vs. 18.8%, p,
0.001). The need for dialysis was not included in our multivariate
analysis because of its collinearity with AKI stage 3.
The overall hospital mortality rate was 38.4% (32.1% in severe
sepsis patients and 54.7% in patients with septic shock in the first
Table 2. Severe sepsis characteristics and treatment.
All patients (n =190) Survivors (n=117) Non-survivors (n=73) p value
Site of infection 0.006
Respiratory 113 (59.5) 66 (56.4) 47 (64.3)
Urinary 32 (16.8) 28 (23.9) 4 (5.4)
Abdominal 18 (9.5 8 (6.8) 10 (13.7)
Others 27 (14.2) 15 (12.8) 12 (16.4)
SIRS criteria
Tachypnea 142 (74.7) 84 (71.7) 58 (79.4) 0.230
Tachycardia 129 (67.9) 80 (68.3) 49 (67.1) 0.850
Leukocytosis 50 (26.3) 28 (23.9) 22 (30.1) 0.340
Leukopenia 31 (16.3) 16 (13.6) 15 (20.5) 0.210
Fever 46 (24.2) 32 (27.3) 14 (19.1) 0.200
Hypothermia 12 (6.3) 7 (5.9) 5 (6.8) 1.000
Organ failures
Respiratory 84 (44.2) 43 (36.7) 41 (56.1) 0.008
Cardiovascular 78 (41.1) 49(41.8) 29 (39.7) 0.760
Renal 77 (40.5) 51 (43.5) 26 (35.6) 0.270
Hematologic 64 (33.9) 30 (25.6) 34 (46.6) 0.030
Neurologic 50 (26.3) 26 (22.2) 24 (32.8) 0.100
Metabolic 13 (7.9) 5 (4.8) 8 (12.9) 0.070
Hepatic 9 (4.7) 6 (5.1) 3 (4.1) 1.000
Admission ,0.0001
Emergency 110 (57.9) 83 (70.9) 27 (36.9)
Ward 80 (42.1) 34 (29.0) 46 (63.0)
Number of organs dysfunctions ($2) 117 (61.5) 65 (55.5) 52 (71.2) 0.030
Glycemia (mg/dl)a 149 (121–194) 151 (121–195) 141 (119–193) 0.360
Time to sepsis diagnosis (hours) 2.5 (1.1–5.2) 2 (0.9–4.2) 3.5 (1.5–6.3) ,0.001
Time to antibiotics (minutes) 55 (30–120) 60 (30–120) 45 (20–80) ,0.001
Duration of ICU stay (days) 6 (3–13) 6 (3–11) 7 (3–16) 0.130
Duration of hospital stay (days) 20 (12–35) 21 (14–38) 15 (8–31) 0.010
Compliance to severe sepsis bundle
Measure lactate 164 (86.3) 103 (88.0) 61 (83.5) 0.300
Broad-spectrum antibiotics 173 (91.0) 107 (91.5) 66 (90.4) 0.800
Blood cultures before antibiotics 151 (79.5) 93 (79.4) 58 (79.5) 0.990
Fluid resuscitation b 54 (62.3) 39 (75) 15 (44.1) 0.004
CVP .8 mm Hg c 6 (15.8) 2 (11.1) 4 (22.2) 0.370
ScvO2 .70% c 14 (36.8) 7 (38.9) 7 (38.9) 1.000
Initial care bundle 74 (39.0) 45 (38.5) 29 (39.7) 0.800
SIRS: systemic inflammatory response syndrome. ICU: intensive care unit. CVP: central venous pressure, ScvO2: central venous oxygen saturation.
a) median glycemia during the first 24 h of sepsis,
b) indication to administer 20 ml/kg crystalloid for hypotension or lactate $36 mg/dl (n = 86),
c) indication to measure CVP or measure ScvO2 (n = 38). The results are expressed as number (%) or median (IQR: 25%–75%). Chi-squared test and Mann-Whitney U-test
(univariate analysis).
doi:10.1371/journal.pone.0111610.t002
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24 hrs of ICU admission). In the multivariate analysis, the
independent determinants of hospital mortality were male gender,
delta SOFA score 24 h, mechanical ventilation, hematological
dysfunction, admission from ward and AKI stage 3 (Table 5). We
could assess the one-year mortality data in all patients and the rate
was 42.6% (37.2% for severe sepsis and 56.6% for septic shock).
Figure 3 shows the Kaplan-Meier curves for one-year survival
after ICU admission.
Discussion
In our study, we were able to show that the independent risk
factors for hospital mortality in renal transplant recipients with
severe sepsis and septic shock admitted to ICU did not include the
transplant characteristics. There was a lower incidence of SIRS
criteria than previously described in other sepsis studies, and there
was a higher frequency of opportunistic pathogens causing severe
sepsis. We also demonstrated a low increment in the mortality rate
one-year after discharge.
The hospital mortality rate for ICU renal transplant recipients
varies greatly in the literature, and no study has specifically
evaluated septic patients [23–29]. Old Brazilian sepsis data from
private and public ICU have shown higher mortality rates than in
the present study [21,30]. More recent data still shows a higher
mortality rate in Brazil [5] than that reported in some studies
conducted in developed countries [2–4]. There are some possible
explanations for this worst performance. In emerging countries,
there are roughly enough resources but there is still limitation in
access of care both in private and in public health systems. Sepsis
awareness among lay people is restricted which contributes to a
delay in searching for care. The gap between scientific evidence
and bedside and staff’s lack of knowledge, a frequent challenge
even in the developed nations, is probably deeper in such settings.
Our better findings might be partially explained by a shorter time
to sepsis diagnosis [21], which was also associated with survival in
our univariate analysis. In addition, the early management of these
patients, as assessed by the compliance to Surviving Sepsis
Campaign 6-hours bundle [17,18], was higher than those
previously described [21,22]. The importance of high compliance
with the resuscitation bundle to reduce mortality rate was
demonstrated in Brazilian private hospitals [7]. In our study,
there was a significant lower compliance to fluid administration in
non-survivors. Interesting, non-survivors had higher fluid balance
at 72 h. This finding suggests that fluids may be essential in the
earliest phases of treatment, but late administration may be
harmful.
Previous sepsis cohort studies have shown an increment in the
mortality rate for sepsis patients (from 7% to 43%) 12 months after
the initial assessment (hospital or 28-days mortality) [31]. In our
study, no relevant increase in the 12-month mortality rate was
observed compared to the in-hospital mortality rate (42.6% and
38.4%, respectively). This interesting and previously unreported
Table 3. Frequencies of infectious agents identified.
Frequency, n (%)
Gram-negative 49 (45.4)
Escherichia coli 16 (15.0)
Klebsiella pneumonia 13 (12.0)
Pseudomonas aeruginosa 8 (7.4)
Acinetobacter baumanii 6 (5.5)
Enterobacter sp 3 (2.7)
Proteus mirabilis 2 (1.8)
Citrobacter sp 1 (0.9)
Gram-positive 22 (20.4)
Staphylococcus aureus 10 (9.2)
Enterococcus sp 7 (6.5)
Staphylococcus epidermidis 3 (2.7)
Streptococcus pneumoniae 1 (0.9)
Streptococcus viridans 1 (0.9)
Fungi 26 (24.0)
Candida albicans 10 (9.2)
Pneumocystis jiroveci 9 (8.3)
Cryptococcus 2 (1.8)
Histoplasma capsulatum 3 (2.7)
Caˆndida sp 2 (1.8)
Others 11 (10.2)
Mycobacterium turbeculosis 4 (3.7)
Cytomegalovirus 4 (3.7)
Listeria monocytogenes 1 (0.9)
Neisseria meningitidis 1 (0.9)
Salmonella sp 1 (0.9)
doi:10.1371/journal.pone.0111610.t003
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finding might be explained, at least partially, by the fact that our
patients were younger than those in other sepsis cohort studies
[1,21]. Moreover, they were under continuous surveillance in a
transplant center with adequate care during the entire follow-up
period.
Considerable variations were present in our findings compared
to other sepsis epidemiological studies. Our patients had fewer
SIRS criteria. In a cohort, multicenter, observational study in
European countries, Sprung et al. reported that approximately
90% of their septic patients had $3 SIRS criteria, while in our
study only 30% of patients had $3 SIRS criteria [32]. Moreover,
we found that 16.4% of the patients had #1 SIRS criteria. This
profile of systemic inflammatory response has been previously
suggested [19,33]. Sawyer et al. demonstrated that immunosup-
pressed solid organ transplant patients had significantly lower
maximum temperatures and white blood cells counts compared to
non-transplant patients [33]. These findings should be taken into
account in sepsis studies involving transplant patients, as the need
for meeting SIRS criteria to define sepsis could be flawed and may
not adequately reflect the actual incidence of sepsis. In fact, the
current SIRS criteria to define the presence of sepsis has been
criticized even in immunocompetent patients [34].
In our study, the lung was the most common site of infection,
which is in alignment with other sepsis cohort studies [22,35,36].
This finding was expected, as respiratory infection is the leading
cause of ICU admission and acute respiratory failure in renal
transplant recipients [23,26,29,37]. The second major source of
sepsis was the urinary tract. Although this is the most common
infectious complication after renal transplantation [38–40],
urinary infection might not lead to severe sepsis as frequently as
pneumonia even in these immunosuppressed patients. Interest-
ingly, while the data may not be significant, urinary tract infection
seems to be associated with lower mortality rates, as previously
showed in immunocompetent patients [41]. We also found a
higher frequency of microbiologically documented infection by
opportunistic pathogens compared with non-transplant patients
[1,8]. This finding was also expected, as infections caused by
opportunistic pathogens in solid organ transplant recipient are
frequent [42]. However, admissions for severe sepsis did not occur
during periods of intensified immunosuppression (in the first
months after transplantation or after treatment for acute rejection).
Our analysis showed that the classical factors usually associated
with morbidity in this population, such as immunosuppressive
regimens, previous rejection treatment and CMV disease, had no
prognostic value. Although delayed graft function was associated
with mortality, it did not remain in our final multivariate logistic
regression model. The only other variable associated with
mortality in the univariate analysis, expanded criteria donor,
could not be included in the model as it was assessed only in the
subgroup that received a deceased-donor kidney. This result aligns
with other studies in critically ill renal transplant patients requiring
ICU treatment [23,25,26,29].
Delta SOFA after 24 hours of ICU admission, the need of
mechanical ventilation, the presence of hematologic dysfunction
and admission from the ward and not from the emergency
department were previously described as mortality risk factors in
critically ill general septic patients [21,22,35,43–45]. The most
controversial risk factor found in our study was male gender.
Clinical sepsis studies evaluating gender-mortality relationships are
inconsistent [46–49]. Recent studies have suggested that although
the incidence of sepsis is greater in men, in-hospital mortality is
significantly higher among women [48,49]. It is possible that
gender influences outcomes differently in renal transplant patients.
An example of these possible interactions is the reports that grafts
from male donors show a trend towards better five-year survival
compared to grafts from female donors [50]. Moreover, we did not
have data about hormonal concentrations. The complexity of
influencing factors did not allow us to evaluate the possible
pathophysiological reasons for our finding.
Figure 2. Frequency of systemic inflammatory response signs on intensive care unit admission.
doi:10.1371/journal.pone.0111610.g002
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The degree of renal allograft dysfunction during ICU stay was
also associated with hospital mortality. As there is no validated
classification for AKI in renal transplant recipients, we used a
KDIGO definition during the ICU stays [20]. Our results
demonstrated that changes in graft function are important and
associated with significant changes in outcomes. This result aligns
with studies using RIFLE/AKIN definitions in which a worse
RIFLE or AKIN class is associated with higher mortality and
Table 4. Severity scores at the ICU admission and the events during ICU stay.
All patients (N=190) Survivors (N=117) Non survivors (N=73) p value
SOFA admission 5 (4–8) 5 (4–7) 6 (4–9) ,0.0001
SOFA at 24 h 5 (4–8) 4 (3–6) 7 (5–11) ,0.0001
SOFA at 72 h 5 (3–8) 4 (2–5) 8 (5–11) ,0.0001
Delta SOFA 24 h 0 (21–1) 0 (21–0) 1(0–3) ,0.001
Delta SOFA 72 h 20.5 (22–1) 21 (22–0) 2(20.7–4) ,0.001
Lactate at admission (mg/dl) 10 (7–16) 10 (6–16) 10 (7–18) 0.670
Lactate at 6–12 h (mg/dl) 10 (7–16) 9 (6–13) 12 (8–25) 0.001
Lactate at 24 h (mg/dl) 8 (6–14) 8 (6–10) 13 (7–31) ,0.0001
Delta lactate 6–12 h (mg/dl) 1 (23–4) 0 (25–2) 4 (0–8) ,0.001
Delta lactate 24 h (mg/dl) 0 (24–3) 22 (26–1) 3 (0–13) ,0.001
APACHE II score 20 (16–23) 18 (15–22) 21 (18–24) 0.004
Septic shock 53 (27.9) 24 (20.5) 29 (39.7) 0.004
Shock after 24 h 96 (50.5) 29 (24.7) 67 (91.7) 0.004
Mechanical ventilation 90 (47.4) 25 (21.3) 65 (89.0) ,0.0001
Hemodialysis 77 (40.5) 22 (18.8) 55 (75.3) ,0.001
AKI classification ,0.0001
Stage ,3 96 (50.5) 80 (68.4) 16 (21.9)
Stage 3 94 (49.5) 37 (31.6) 57 (78.1)
Reinfection in ICU 34 (17.9) 18 (15.3) 16 (21.9) 0.200
Cumulative fluid balance
First 6 h after severe sepsisa 500 (0–1500) 610 (0–1500) 250 (0–1500) 0.080
First 12 h after severe sepsisb 1500 (510–2640) 1500 (565–2569) 1175 (385–2736) 0.350
First 72 h after severe sepsisc 4634 (3192–6959) 4301 (3163–6208) 6099 (3657–8391) 0.007
First 6 h after septic shockd 1500 (774–2069) 1500 (790–2000) 1608 (750–2678) 0.710
First 12 h after septic shocke 2190 (1609–3231) 2000 (1394–3036) 2428 (1820–3330) 0.350
First 72 h after septic shockf 6928 (4598–8926) 5460 (2096–7117) 8750 (6928–13162) 0.001
SOFA: Sequential Organ Failure Assessment score, APACHE II: Acute Physiological and Chronic Health Evaluation II score, AKI: acute kidney injury (from KDIGO), ICU:
intensive care unit.
a) n = 189,
b) n = 188,
c) n = 153,
d) n = 50,
e) n = 46,
f) n = 34. Results are expressed as number (%) or median (IQR: 25%–75%). Chi-squared test and Mann Whitney U-test (univariate analysis).
doi:10.1371/journal.pone.0111610.t004
Table 5. Multivariate logistic regression analysis in septic transplant patients with hospital mortality as dependent factor.
OR (95% CI) p value
Male gender 5.9 (1.7–19.6) 0.004
Delta SOFA 24 h (per point increase) 1.7 (1.2–2.3) 0.001
Mechanical ventilation 30.0 (8.8–102.2) ,0.0001
Hematological dysfunction 6.8 (2.0–22.6) 0.002
Sepsis admitted from ward 3.4 (1.2–9.7) 0.020
AKI stage 3 5.7 (1.9–16.6) 0.002
OR: odds ratio, CI: confidence interval, SOFA: Sequential Organ Failure Assessment, AKI stage 3: acute kidney injury stage 3.
doi:10.1371/journal.pone.0111610.t005
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longer ICU or hospital stay [20]. This study is the first in renal
transplant recipients to use a new approach of AKI classification to
associate the degree of renal dysfunction with mortality. A
previously reported by Nakamura et al., higher acute kidney
injury states correlate with lower graft survival rates. However, the
authors did not present mortality as an outcome [51].
Our study had strengths and limitations. We included a
homogeneous population of renal transplant recipients in a
consecutive fashion. We assessed several transplant and sepsis
characteristics, including treatment adequacy, which could inter-
fere with patient outcomes. In addition, we used a new AKI
classification approach. These contributions are relevant consid-
ering the paucity of data currently available in the literature. The
study also has some limitations, the most important being the
retrospective nature of our data collection. Second, our study has a
single-center design, which limits the reproducibility of our
findings. Third, we did not have a control group with septic
non-transplanted patients and transplanted patients without sepsis.
Fourth, we limited our analysis to ICU patients and did not
include patients with severe sepsis in other hospital settings. The
relevance of this limitation should have been minimized because in
this institution, the vast majority of the septic patients are admitted
to the ICU. Fifth, a better characterization of AKI is lacking. We
do not have data regarding estimated glomerular filtration rate,
time for dialysis onset or its duration, and long-term graft function.
Moreover, we did not assess the role that acute rejection could
have played in graft dysfunction. We also only consider creatinine
and not diuresis in our AKI classification, which may have
underestimated the number of patients with late stage diseases.
However, controversy exists regarding the impact of this
assessment in the score ability to predict prognosis [52]. Sixth,
we have no data regarding adrenal insufficiency in our study.
Besides the possibility of corticosteroid insufficiency related to
critical illness or sepsis, previous chronic use of prednisone in
nearly all patients could suppress the hypothalamic-pituitary-
adrenal axis (HPA). This was the main reason for hydrocortisone
administration. Another reason was the need for immunosuppres-
sant drugs to prevent rejection, since all other immunosuppressant
agents were discontinued at ICU admission.
Conclusion
Hospital mortality in renal transplant patients with severe sepsis
and septic shock was associated with male gender, admission from
the wards, worse SOFA scores on the first day and the presence of
hematologic dysfunction, mechanical ventilation or advanced graft
dysfunction. Transplant-related variables had no prognostic value.
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